Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 1;16(3):631.
doi: 10.3390/cancers16030631.

Recurrence and Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Synchronous and Metachronous Peritoneal Metastases of Colorectal Origin

Mette Fugleberg Nielsen  1 , Sissel Ravn  1 , Mette Møller Sørensen  1 , Jonas Amstrup Funder  1   2 , Lene Hjerrild Iversen  1   2
Affiliations

Recurrence and Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Synchronous and Metachronous Peritoneal Metastases of Colorectal Origin

Mette Fugleberg Nielsen et al. Cancers (Basel). .

Abstract

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has improved the 5-year survival for colorectal cancer (CRC) patients with peritoneal metastases (PM). Little is known about recurrence patterns and recurrence rates between synchronous (S) and metachronous (M) PM following CRS+HIPEC. We aimed to describe the recurrence patterns, overall survival (OS) and disease-free survival (DFS) in S-PM and M-PM patients after complete CRS+HIPEC. From June 2006 to December 2020, a prospective cohort study included 310 CRC patients, where 181 patients had S-PM (58.4%) and 129 patients had M-PM (41.6%). After a median 10.3-month follow-up, 247/310 (79.7%) patients experienced recurrence, and recurrence sites included isolated peritoneal (32.4%), multifocal (peritoneal and liver and/or lung(s)) (22.7%), isolated liver (17.8%), isolated lung (10.5%) and other (16.6%) sites. Recurrence patterns did not differ between S-PM and M-PM. M-PM patients had an impaired DFS compared to S-PM patients (9.4 months (95% CI: 7.3-12.1) vs. 12.5 months (95% CI: 11.2-13.9), p = 0.01). The median OS was similar for S-PM and M-PM (38.4 months (95% CI: 31.2-46.8) vs. 40.8 months (95% CI: 28.8-46.8), p = 0.86). Despite frequent recurrence at extraperitoneal locations, long-term survival was achievable after CRS+HIPEC in CRC patients with PM. The recurrence patterns and OS did not differ between groups, yet M-PM patients had a shorter DFS.

Keywords: colorectal cancer; cytoreductive surgery; hyperthermic intraperitoneal chemotherapy; metachronous peritoneal metastases; prognosis; recurrence; synchronous peritoneal metastases.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
The cumulative incidence proportion of recurrence for the total population.
Figure 2
Figure 2
Disease-free survival for patients with synchronous and metachronous peritoneal metastases.
Figure 3
Figure 3
Overall survival for patients with synchronous and metachronous peritoneal metastasis.
See this image and copyright information in PMC

References

    1. Danish Colorectal Cancer Database (DCCG) Landsdaekkende Database for Kraeft i Tyk-Og Endetarm. [(accessed on 29 January 2023)]. Available online: https://dccg.dk/ (In Danish)
    1. Majano S.B., Girolamo C.D., Rachet B., Maringe C., Guren M.G., Glimelius B., Iversen L.H., Schnell E.A., Lundqvist K., Christensen J., et al. Surgical Treatment and Survival from Colorectal Cancer in Denmark, England, Norway, and Sweden: A Population-Based Study. Lancet Oncol. 2019;20:74–87. doi: 10.1016/S1470-2045(18)30646-6. - DOI - PMC - PubMed
    1. Lurvink R.J., Bakkers C., Rijken A., van Erning F.N., Nienhuijs S.W., Burger J.W., Creemers G.J., Verhoef C., Lemmens V.E., Hingh I.H.D. Increase in the Incidence of Synchronous and Metachronous Peritoneal Metastases in Patients with Colorectal Cancer: A Nationwide Study: Colorectal PM: Incidence & Associated Factors. Eur. J. Surg. Oncol. 2021;47:1026–1033. doi: 10.1016/j.ejso.2020.11.135. - DOI - PubMed
    1. Quere P., Facy O., Manfredi S., Jooste V., Faivre J., Lepage C., Bouvier A.M. Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study. Dis. Colon Rectum. 2015;58:743–752. doi: 10.1097/DCR.0000000000000412. - DOI - PubMed
    1. Ravn S., Christiansen C., Hagemann-Madsen R., Verwaal V., Iversen L. The Validity of Registered Synchronous Peritoneal Metastases from Colorectal Cancer in the Danish Medical Registries. Clin. Epidemiol. 2020;12:333–343. doi: 10.2147/CLEP.S238193. - DOI - PMC - PubMed

LinkOut - more resources